Layout Table~~~~2066~2066~~

Cancer Antibodies: Competitive Positioning for Success~
Published by BioSeeker Group, June 2008

This report aims to analyze the current and future potential of cancer antibodies by examining key fundamentals across the entire pipeline of antibody drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landscape within the pharmaceutical industry; compound type, therapy area and target type.~Published by BioSeeker Group, June 2008

This report aims to analyze the current and future potential of cancer antibodies by examining key fundamentals across the entire pipeline of antibody drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landscape within the pharmaceutical industry; compound type, therapy area and target type.

This report is written for you to identify your competition and understand which targeting strategies are at work within antibody drug development. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your own drug development and who are developing sequels to blockbuster drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversely it may reveal unexpected competition for you.

Drug targets are the critical link between drugs and their role in the treatment of medical disorders. BioSeeker has surveyed the cancer antibody field and identified 145 drug targets belonging to 253 antibodies. This report, Cancer Antibodies: Competitive Positioning for Success, is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of cancer antibody drugs.

In the report, BioSeeker reports on 147 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 253 cancer antibody drugs designed for the treatment of 42 different cancer indications. The highest degree of distinctiveness among cancer antibodies is achieved by sorting each of them according to targeted cancer indication and drug target mix. At the same time we are also identifying peer groups of drugs, that is, drugs we consider suitable for head-to-head comparison during drug development.

To fuel the scientific and competitive thinking, BioSeeker opens the gate into the presence and relevance of protein-protein interactions between identified targets of cancer antibodies. No less than 165 protein-protein interactions were recognized among and between 98 of the 145 included antibody drug targets.

Why You Should Own Your Own Copy of this Report:

• 260+ pages, with almost a hundred different tables and figures. Includes more than 1,000 active links to drug target related resources on the Internet
• A 253 cancer antibody drugs analysis, under development by 102 investigators, covering 480 developmental projects in cancer
• 145 unique, in-depth, drug target validating profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other antibody drug targets, pursued cancer indications, drugs under development, presence in the Cancer Genome Project etc.
• A unique drug target combination breakdown of cancer antibodies into tumor type and developmental stage
• Unique drug-protein target interactome- and protein-protein of drug targets interactome analysis
• Pathway profiling of cancer antibody drug targets
• Pin-point which competitor drugs’ clinical out-come may have bearing on your own drug development
• Who are working on sequels to blockbuster drugs?
• Locate white-spots in the competitive landscape, giving you little or no competition

In all, this report is a serious reference for any professional interested in the development of oncology drug targets and the selection/validation of targeting strategies.

Sample Pages~Cancer Antibodies%3A Competitive Positioning for Success (PDF or Hard Copy)|1200|~2066~3365~~

Triple Analysis: Apoptosis Agents, Antibodies and Vaccines in Oncology~
Published by BioSeeker Group, December 2006

In this triple analysis report BioSeeker Group has analyzed three major and intertwined areas of cancer R&D, Apoptopic agents, Antibodies and Vaccines in Oncology, which are all subjects to an extensive number of innovative drug candidates. This extensive 350+ pages report compiles and analyzes in parallel the progress concerning drug development and competitive situation in the three mentioned key oncology areas. The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors.~Published by BioSeeker Group, December 2006

In this triple analysis report BioSeeker Group has analyzed three major and intertwined areas of cancer R&D, Apoptopic agents, Antibodies and Vaccines in Oncology, which are all subjects to an extensive number of innovative drug candidates. This extensive 350+ pages report compiles and analyzes in parallel the progress concerning drug development and competitive situation in the three mentioned key oncology areas. The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors.

There are today over 190 apoptopic drugs in active development for the treatment of more than 40 different cancer indications. The top five pursued cancer indications are: breast cancer, leukemia, lung cancer, lymphoma and prostate cancer. A thorough target analysis of drugs in development reveals more than 130 candidate targets for triggering apoptosis in cancer cells.Competitive forces are reviewed, showing market leaders, active players and changes in the competitive landscape. There are only one big pharma company represented among the top 10 players in apoptopic drug development in oncology. The acquisition of Idun Pharmaceutical in 2005 by Pfizer is principal example of a further step in big pharma strategy to augment their internal research and development efforts with high-potential, externally sourced product candidates and technologies.

Apoptopic Agents Highlights

In-depth competitive landscape assessment of the apoptopic market in oncology
Thorough review of utilized targets in apoptopic drug development
Thorough review of approved drugs
Progress analysis of five major cancer indications, including players, drugs, clinical progress and pitfalls
Among the targeted therapies for cancer, immunotherapy is probably the most versatile treatment strategy for the eradication of tumors, metastatic spread or not. Main strategies of cancer immunotherapy aim at exploiting the therapeutic potential of tumor-specific antibodies and cellular immune effector mechanisms (vaccines).

Immunotherapy in Highlights

In-depth competitive landscape assessment of the cancer immunotherapy market place; Including more than 200 immunotherapy drugs and pharmaceutical companies
Thorough review of tumor antigen discovery, immunomodulating strategies and adjuvants
Thorough review of antibody and vaccine delivery and technologies surrounding it - The next generation
Progress analysis of six major cancer vaccine indications and late stage antibody development projects, including players, drugs, clinical progress and pitfalls

Pages: 350+

Table of Contents~Triple Analysis%3A Apoptosis Agents, Antibodies and Vaccines in Oncology (PDF)|1085|Triple Analysis%3A Apoptosis Agents, Antibodies and Vaccines in Oncology (Hard Copy)|1086|~2066~3280~~

Antibodies in China~
Published by General Biologic, February 2005

This report provides a comprehensive resource to companies, investors, and entrepreneurs interested either in accessing China’s market for antibody products or cost-effective production of antibodies for therapeutic, diagnostic, or laboratory use. An overview and analysis of the antibody industry in China, including three case studies of leading companies in provided as well as a comprehensive directory of more than 30 antibody-related enterprises including English and Chinese names, contact information, and products and services. The report also features detailed profiles of companies that offer custom preparation services, including animal and purification methods used, English and Chinese names, and contact information.~
Published by General Biologic, February 2005

The purpose of this report is to provide a comprehensive resource to companies, investors, and entrepreneurs interested either in accessing China's market for antibody products or cost effective production of antibodies for therapeutic, diagnostic, or laboratory use.
It includes

• Overview and analysis of the antibody industry in China, including three case studies of leading companies
• Comprehensive directory of more than 30 antibody-related enterprises including English and Chinese names, contact information, and products and services provided.
• Detailed profiles of companies that offer custom preparation services, including animal and purification method used,
• English and Chinese names, and contact information.
• Diagnostic and therapeutic antibody-related information.

o Diagnostic and therapeutic antibody markets in China
o Regulatory environment
o Candidate therapeutic antibodies
o Innovators

Who benefits from this report?

• Managers and scientists
• Pharmaceutical companies
• Biotechnology companies
• Research institutes
• Distributors
• Investors
• Entrepreneurs

Why is this report unique?

• This report is the first to cover China's emerging antibody industry Methodology
• Face-to-face interviews and on-site visits
• Phone interviews with management
• Internet research

Table of Contents~Antibodies in China|347|~2066~1938~~